We are redefining the entire journey from conditioning to cure, unlocking the full potential of HSC therapy to deliver lasting outcomes for millions of patients.
Inograft was founded by scientists and entrepreneurs led by Irv Weissman, whose discoveries have reshaped hematology, immunology, and stem cell biology. His pioneering research revealed how blood and immune systems regenerate and led to the first isolation of hematopoietic stem cells.
Building on this foundation, his group and Inograft’s co-founders developed antibody-based, non-genotoxic conditioning to address the limitations of chemotherapy and radiation. Today, Inograft is advancing the science to redefine conditioning and unlock the full potential of blood stem cell transplantation.
Our strategy is a stepwise approach to dismantle the barriers limiting transplantation one after another.
Our initial focus is on the most critical barrier to successful HSCT: conditioning. Inograft is pioneering a targeted biologic approach to enable HSCT with greater precision and safety. Our approach has three key components:
Target Biology— Defining What Must Change for Cure
Standard transplant protocols use chemotherapy and radiation to clear out the entire host blood system, but these approaches also damage healthy tissues, contributing to serious toxicities and long-term complications. Inograft is taking a fundamentally different path: by precisely identifying the specific cells and immune barriers that must be cleared to enable hematopoietic stem cell engraftment, we can avoid the need for these harmful treatments.
Rooted in research from Irv Weissman’s lab at Stanford University, our team brings deep expertise in isolating and characterizing hematopoietic stem cells and immune cells. Using advanced mass spectrometry and RNA sequencing, we’ve built a discovery engine that pinpoints the key cellular targets required for durable engraftment.
Selective Engineering — Replacing Toxicity with Precision
Guided by this biological insight, Inograft has developed a suite of best-in-class biologics designed to achieve conditioning with exceptional selectivity.
These targeted therapies deplete a patient’s blood forming stem cells without injury to non-hematopoietic tissues, enabling faster recovery, preserving fertility, and reducing the risk of chronic organ damage.
Translation to Patients — Accelerating Predictive and Safe Development
Each therapeutic concept is advanced through predictive preclinical models that closely mirror human hematopoiesis and immune function.
These systems provide early, reliable insight into depletion, engraftment, and safety – guiding molecule selection and dose optimization before entering the clinic. By building translational confidence early, we aim to accelerate development and maximize the probability of success in first-in-human studies.